Hormonal
GLP-1 receptor agonists (GLP-1RAs) provide significant cardiorenal protection in patients with type 2 diabetes and obesity, reducing major adverse cardiovascular events (MACE) and slowing kidney disease progression independent of, or in addition to, glycemic control and weight loss.
If you have type 2 diabetes or obesity with heart/kidney risks, GLP-1 medications (like semaglutide or liraglutide) are highly effective. They don't just lower blood sugar; they significantly reduce the risk of heart attacks, strokes, and kidney failure. While they can cause temporary stomach upset, the long-term benefits for your heart and kidneys are substantial and proven by large clinical trials. Discuss these options with your doctor, especially if you have existing heart or kidney conditions.
GLP-1RAs have consistently demonstrated robust HbA1c- and body weight–reducing efficacy in clinical and real-world studies. In addition, mounting data established their cardiorenal benefits beyond glycaemic control in select high-risk populations.
Why this rating
Supported by multiple large-scale Phase 3 randomized controlled trials (CVOTs) and dedicated kidney outcome trials (e.g., FLOW, SELECT).
Source
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Ellen M. Apperloo et al. · Nephrology Dialysis Transplantation · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →